Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer

BACKGROUND: To evaluate the efficacy of lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, in therapy-resistant HER2-positive CTCs in metastatic breast cancer (MBC). PATIENTS AND METHODS: Patients with MBC and HER2-positive CTCs despite disease stabilization or response to prior therapy, rec...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Agelaki, Sofia, Kalykaki, Antonia, Markomanolaki, Harris, Papadaki, Maria A., Kallergi, Galatea, Hatzidaki, Dora, Kalbakis, Kostas, Mavroudis, Dimitrios, Georgoulias, Vassilis
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4471111/
https://ncbi.nlm.nih.gov/pubmed/26083256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0123683
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars